Inhibrx ROCE
Quel est le ROCE de Inhibrx?
Le ROCE de Inhibrx, Inc. est 758.45%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur NASDAQ par rapport à Inhibrx
Que fait Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Entreprises avec roce similaire à Inhibrx
- Molecular Data Inc a ROCE de 682.69%
- 9 Meters Biopharma a ROCE de 684.23%
- Biosig Technologies Inc a ROCE de 689.29%
- BioCardia a ROCE de 724.72%
- Elfato a ROCE de 731.09%
- ContraFect Corp a ROCE de 754.78%
- Inhibrx a ROCE de 758.45%
- Corvus Gold a ROCE de 760.11%
- Havn Life Sciences Inc a ROCE de 763.04%
- Sabine Royalty Trust a ROCE de 785.68%
- Winners a ROCE de 793.33%
- American Environmental a ROCE de 831.71%
- Killi a ROCE de 837.33%